BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank check company focused on the oncology and life sciences therapeutics sector, operating under sponsorship affiliated with the BridgeBio name. The company filed a Form 10-Q with the Securities and Exchange Commission on August 14, 2024, covering its quarterly financial position as a special purpose acquisition company actively searching for a business combination target. BBOT completed its initial public offering in 2024 and remains in the pre-combination phase as of its most recent quarterly disclosure. The filing reflects the company's ongoing search for an appropriate merger candidate in the biopharmaceutical and oncology space. Sign up at SpacDesk for full filing data, timeline analytics, and deal-tracking coverage on BBOT and hundreds of active SPACs.